L analysis (I2 = 26 , p = 0.17). ARBs were not associated with a

L analysis (I2 = 26 , p = 0.17). ARBs were not associated with a reduction
L analysis (I2 = 26 , p = 0.17). ARBs were not associated with a reduction in all-cause mortality (RR: 1.03, 95 CI: 0.98?.08, p = 0.28, Fig. 3). Similar findings were observed when comparing with placebo or ACEIs (p 0.60, Fig. 3). And there was no evidence of publication bias (p = 0.921).Fig. 1 Flow diagram of selection strategy. ACEI, angiotensin-converting enzyme inhibitor, ARB, angiotensin II receptor blockerTable 1 Study characteristicsDrugs Treatment Irbesartan Candesartan Candesartan Candesartan Valsartan Candesartan Placebo 68 67 0.40 135 6 68 27 0.40 12 12 12 48 72 43 130 107 12 ?4 ???12 12 12 27 12 0.35 ??59 80 72 68 61 68 63 ?0.40 82 0.35 0.35 ?Digoxin 24 12 12 144 166 96?00 216 ???????100 ?100 ????13 ??????????100 0 100 0 0 0 47 ?72 ??????0 0 44 ?68 ???69 3 ??87 ???0 0 3 ???12 0.45 <0.35 0.40 0.40 <0.40 <0.35 0.35?.45 0.45 ?60 24 ?<0.40 ?0.35 ?0.35 ????????25 24 ?17 23 ???70 48 ?73 ??????????30 30 ?15 ???????????8 ?26 ????????12 ?23 ??23 ????21 26 14 ????Placebo 80 63 0.40 100 7 57 31 26 ???50 Placebo 78 64 0.45 24 25 7 57 8 ???Placebo 69 66 <0.35 12 ?4 71 16 11 48 34 24 ?12 25 Placebo 68 62 0.35?.45 12 ?29 71 2 2 ???Placebo 82 60 0.40 12 67 ???????2 4 5 4 5 5 Control Men, Age, y LVEF, MI, HTN, ICM, NICM, VHD, DM, HTN, AF, Baseline characteristics RDX5791 supplier pubmed ID:https://www.ncbi.nlm.nih.gov/pubmed/28388412 Followup, w Cause of heart failure Risk factors Jadad ScoreStudy, yearNo of patientsARBs vs ControlsHavranek [43],STRETCH PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28914615 [45],SPICE [44],ARCH-J [47],Val-HeFT [46],CHARM-Alternative [13],ARBs vs ACEIs Telmisartan Valsartan Losartan Losartan Losartan Candesartan Losartan Valsartan Losartan Enalapril 78 58 Captopril 69 65 Captopril 71 67 Enalapril 84 63 Captopril 70 71 Captopril 67 73 Enalapril 78 64 Enalapril 75 67 Enalapril 89 64 ??23 57 49 ?36 55 ?28 ????25 ????43 42 23 ????23 30 ?10 ???????58 ?????10 ??4 3 3 4 5 5 5 5REPLACE [42],Tai et al. BMC Cardiovascular Disorders (2017) 17:HEAVEN [40],Dickstein [39],ELITE [14],ELITE II [10],RESOLVD [12],OPTIMAAL [9],VALIANT [11],14,Lang [41],ACEIs vs Controls Ramipril Captopril Enalapril Lisinopril Benazepril Enalapril Fosinopril Fosinopril Perindopril Captopril Captopril Enalapril Trandolapril Captopril Placebo Placebo Placebo Placebo ?Placebo ??Placebo 80 62 Placebo 74 63 Placebo 70 71 Placebo ??Placebo 69 58 Placebo 83 58 Placebo ??Placebo 74 65 5 2 3 2 2 3 4 3 3 2 5 5 5AIRE [2],Balpitt [23],CASSIS [24],Chalmers [25],Colfer [26],CONSENSUS [3],FEST [27],FHFSG [28],Lechat [29],Newman [30],SAVE [4],SOLVD [5],TRACE [6],Page 4 ofAguilar [31],Table 1 Study characteristics (Continued)Drugs Treatment Enalapril Enalapril Captopril Captopril Captopril Lisinopril Captopril Enalapril Enalapril Nitrates ?61 <0.45 96 ?????Omapatrilat 79 63 0.30 58 56 ????31 20 Candoxatril 87 63 <0.40 12 ??????Omapatrilat 89 64 ?>40 4 66 24 3 ?????48 Hydralazine 86 52 0.2(m) 32 ?59 34 4 ???Ibopamine 84 62 <0.40 24 ?6 67 27 8 ??Flosequinan ?48 15 17 ???14 ??????????Bisoprolol 71 73 0.35 96 25 61 12 12 21 59 54 ?5 3 3 3 5 2 5 3 Carvedilol 80 62 <0.40 72 ?14 32 17 4 ????Control Men, Age, y LVEF, MI, HTN, ICM, NICM, VHD, DM, HTN, AF, Baseline characteristics Followup, w Cause of heart failure Risk factors Jadad ScoreStudy, yearNo of patientsCARMEN [32],CIBIS III [33],Cowley [34],Dohmen [35],Hy-C [36],IMPRESS [37],Northridge [38],OVERTURE [7],Tai et al. BMC Cardiovascular Disorders (2017) 17:V-HeFT II [8],Data was absent in the original article No number, LVEF left ventricular ejection fraction, MI myocardial infarction, HTN hypertension, DM.